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Intermittent Pneumatic Compression Devices –
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There are many reports of how IPC is used effectively in the clinical setting; including the prevention of deep venous
thrombosis, improvement of circulation in patients with lower extremity arterial diseases, reduction of lymphoedema, and
the healing of venous ulcers. However, despite the widely accepted use of IPC, it is still unclear how IPC actually exerts
its beneficial effects. The exact physiological mechanisms of action are unknown. The clinical utility of IPC and the
putative mechanisms by which IPC could exert its therapeutic effect will be reviewed. The paper will examine the
mechanical effects of IPC exerted on the lower extremity, and the subsequent biochemical changes in the circulation. In
vitro studies of the effects of mechanical stress such as compressive strain and shear on cultured endothelial cells, and
their clinical relevance to IPC will also be reviewed.
Key Words: Pneumatic compression; Mechanical stress; Fibrinolysis; Prostacyclin; Cyclic strain; Shear stress; Venous
insufficiency; Deep venous thrombosis; Arterial insufficiency; Venous stasis; Plasminogen activator inhibitor; Tissue
factor pathway inhibitor; Tissue plasminogen activator.
Introduction arteriosclerosis and thromboangiitis obliterans, Ray-
naud’s disease, and foot ulcers.4 Landis and Gibbon
expanded this use of pressure-suction technique toAs early as the 1800s, physicians have experimented
include the treatment of ischaemic limb, chronic ulcers,with the concept of improving blood circulation by
and claudication.5,6exerting external pressure on the legs. There were
Today, intermittent pneumatic compression (IPC)many documented uses of an assortment of suction
devices are primarily used in the prevention of deepdevices to treat diseases ranging from cholera to throm-
venous thrombosis (DVT). Less common uses of IPCboangiitis obliterans.1–3 In 1934, Mont Reid and Louis
include the treatment of venous ulcers, lymphoedema,Herrmann proposed the use of alternating pressure
venous insufficiency, arterial occlusive disease, pre-and suction in what they called, ‘‘PAVAEX’’ (Passive
vention of haematoma, pretibial mucinosis, and giantvascular exercise), to treat various forms of lower
haemangiomas (Table 1). However, despite the widelyextremity arterial diseases. They devised an apparatus
accepted use of IPC for the treatment of arterial andthat consisted of a control box and a chamber. Patients
venous diseases, it is still unclear how IPC actuallyplaced their lower extremity into this chamber, which
exerts its beneficial effects. The exact physiologicalthen subjected the limb to various amounts of negative
mechanisms of action are unknown. This paper willand positive pressure. Reid and Herrmann noted
review the clinical utility of IPC and the putativethat cycling 20–40 mmHg of positive pressure
mechanisms by which IPC could exert its therapeuticwith 80 mmHg negative pressure over 20 s improved
effect.arterial circulation in patients suffering from
Methods
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Table 1. Clinical utility of intermittent pneumatic compression. in the control group to 2% in the group treated with
IPC.9Prevention of deep venous thrombosis
Orthopaedic surgery7–9 The successful use of IPC in the prevention of DVT
General surgery12 and pulmonary embolism has also been well docu-
Cardiothoracic surgery11 mented in a variety of surgical procedures. In 128Neurosurgery10
Urology12 patients who underwent craniotomy, IPC reduced the
Gynaecologic surgery12 incidence of venous thrombosis from 9 of 49 control
Vascular surgery12 patients (18.4%) to 1 of 53 (1.9%) patients treated with
IPC.10 Moreover, in a study of 2551 patients whoTreatment of lymphoedema13,14
Postmastectomy underwent cardiothoracic surgery over a 10-year
Post radiation treatment period, combining the use of bilateral IPC and sub-
cutaneous heparin reduced the frequency of post-Arterial occlusive disease15
operative pulmonary embolism by 62% compared to
Miscellaneous the prophylactic use of subcutaneous heparin alone.11Prevention of haematoma17
Venous ulcers16 In a study of 500 patients in five surgical specialties
Chronic venous insufficiency16 (general surgery, gynaecological surgery, orthopaedic
Pretibial mucinosis18 surgery, genitourinary surgery, and vascular surgery)Giant haemangiomas19
using several modalities of DVT prophylaxis, the in-
cidence of DVT in the control group was 35.6%, while
the incidence within the heparin, graduated elastic
or ‘‘fibrinolysis’’. Once we had an idea of the various stocking and IPC groups were 25.5%, 14.2%, and 11.5%,
proposed mechanisms of action, we searched for rel- respectively.12
evant papers pertaining to mechanical strain or shear IPC has also been utilised in the treatment of lymph-
that relates to the various mediators listed as possible atic disorders. In a study of 28 women previously
agents relevant to the therapeutic effects of IPC. treated for breast cancer, manual lymph drainage and
IPC were equally efficient in decreasing arm volume.13
IPC treated patients had a 25% observed reduction in
circumference of limb oedema compared to 20% in
Clinical efficacy the control group.14
Peripheral arterial disease is another area in which
IPC is well known as a treatment option for a variety IPC has been used. Intermittent pneumatic foot com-
of circulatory diseases. However, the most widely pression (IPCfoot) has been utilised in treating symp-
accepted application of IPC has been for the prevention tomatic lower extremity claudication. In a study of 37
of DVT and subsequent thromboembolism. IPC is an patients with symptomatic claudication, 25 patients
important modality for DVT prevention in patients received IPCfoot treatments at least 4 h per day for 4.5
undergoing various surgical procedures or in patients months. When compared to the 12 controls, the treated
who have sustained serious trauma. group increased claudication distance by over 100%,
One of the most widely reported successes in using their resting-ankle brachial index (ABI) by 18%, and
IPC for DVT prevention is in patients undergoing post exercise ABI by 110%. Moreover, the treated group
orthopaedic surgery procedures. DVT has been re- increased arterial calf inflow by 36%, which suggested
ported to be as high as 70% in orthopaedic patients who an improved collateral circulation. Maximum benefit
did not receive any prophylactic preventive measures. from this treatment was most evident in the first 3
Pulmonary embolism occurred in up to 6% of these months. Improvement in arterial circulation in some
patients and fatal pulmonary embolism in as many as patients was maintained even 1 year after treatment.15
3.4%.7 In a study of 425 patients who underwent For the treatment of venous ulcers secondary to
total hip arthroplasty, the use of intraoperative and venous insufficiency, 21 of the patients received IPC
postoperative thigh-high IPC combined with duplex and the healing efficiency of these treated patients
ultrasound was effective for prophylaxis against DVT were compared to 24 non-treated patients. Only one
and thromboembolism. Furthermore, the reported low of 24 patients in the control group had complete
rate of DVT (4.6%) and symptomatic PE (0.6%) was healing of all venous ulcers compared with 10 of 21
comparable to the low prevalence achieved with phar- patients healed in the IPC group. The median rate of
macological prophylaxis.8 Similarly, in a study of 104 ulcer healing in the control group was 2.1% area per
patients undergoing either joint replacement or frac- week compared to 19.8% area per week in the IPC
group.16ture repairs, the rate of DVT was reduced from 19%
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Another novel use of pneumatic compression in- enhance popliteal artery blood flow. It was postulated
that the flow increase was due to a dramatic drop includes the prevention of haematoma after varicose
vein stripping. When IPC was applied with a com- the peripheral vascular resistance as the peak systolic
and end diastolic flow velocities increase, and thepression of 40–50 mmHg then held for 24–36 h, the
patient could walk and the pneumatic compression reverse-flow component diminishes.27 This increase in
lower extremity arterial flow was not limited to healthyprevented post-varicose vein stripping haematoma
formation.17 More controversial uses of PC include its individuals. The increase in popliteal artery flow and
foot skin perfusion occurred with patients with clau-use in treating pretibial mucinosis18 and giant
haemangiomas.19 dication as well as in those with occluded superficial
femoral artery.28 The increase in the A–V pressure
gradient and subsequent increase in arterial flow
caused by IPC has been postulated as a possible mech-
Mechanical effects of IPC anism by which IPC improved patients with clau-
dication.15
The sudden application of a uniform external pressure The circumferential compression of the lower ex-
on the lower extremity imposes a striking physiological tremity by IPC also transmits pressure to the sub-
change in the structure and haemodynamics of the cutaneous tissues and the muscle groups. Compression
lower extremity. If we focus on the deep veins there increases the interstitial pressure in the extracellular
is a slow steady flow of blood within its lumen prior space. When the interstitial pressure is greater than the
to compression. When compression is applied, the hydrostatic pressure within the vessels, third spaced
sudden pressure gradient at the compression zone fluids are forced back into circulation. This phe-
accelerates the blood forward with a subsequent col- nomenon effectively decreases the cross-sectional area
lapse of the lumen at the compression zone, effectively of the lower extremity and decreases the tensile stretch
facilitating venous emptying and preventing stasis. on the cutaneous tissues; especially in patients with
The accelerated blood moves forward as a pulsatile an oedematous lower extremity. The decreased surface
volume that causes distention of the compliant lumen. tension may provide improved transcutaneous oxy-
This distention exerts up to a 20% strain on the endo- genation and clearance of metabolic toxins.29
thelial cells when an external pressure of 50 mmHg is However, the exact mechanism by which IPC aids
applied.20 Moreover, if the pressure is applied se- in venous ulcer healing remains unclear. In a study of
quentially, the accelerated blood flow could increase 10 patients with post-thrombotic leg ulcers, trans-
the peak flow velocity by over 200% within the lumen.21 cutaneous oxygen tension (TcPO2) was higher after
The higher flow velocity increases the shear stress on treatment with IPC (42.7 mmHg) compared to before
the endothelial cells lining the lumen, which may also treatment (26.2 mmHg). It was postulated that IPC
facilitate clearance of the valve sinuses. decreased interstitial fluid volume and venous stasis,
The different modality of external compression was both of which lead to increased cutaneous tissue oxy-
studied using a computer-simulated model. It was genation.29 However, other reports do not confirm this
found that a sequentially applied wavelike com- finding. Nemeth demonstrated that oedema removal
pression provides the most efficient method of venous by pneumatic compression did not alter TcPO2.30 In a
emptying, suggesting that a sequential compression study of 21 healthy adults and 23 elderly patients,
device may more efficacious in preventing DVT.22 another group found that TcPO2 was decreased and
IPC’s effect of altering lower extremity hemo- TcPCO2 increased during IPC.31 The data suggests that
dynamics is not limited to the venous system. By using the role of enhancement of cutaneous oxygenation
venous plethysmography and heat flow calorimetry and CO2 removal by IPC on wound healing is still
it could be demonstrated that venous pressure was unresolved.
lowered and blood flow was increased in the foot in
subjects that received IPC.23 The improved emptying
of lower extremity veins and lowered venous pressure
led to an increase in A–V pressure gradient. The Biochemical effects
increased disparity of A–V pressure also caused an
increase in lower extremity arterial blood.24 Fur- A seminal observation was that when IPC was applied
to the upper extremities, the incidence of DVT in thethermore, IPC has been reported to increase in the
mean popliteal artery flow by as much as 93%.25,26 lower extremities could be lowered.32 This finding
suggested that IPC’s efficacy in lowering the rate ofIn a study of 40 lower limbs of 30 volunteers,
the application of IPC was demonstrated to greatly DVT was not solely the direct result of mechanical
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Fig. 1. Mechanical effects of pneumatic compression on a vein or artery. The pneumatic compression increases intravascular flow, shear
and compressive strain on endothelial cells with the resulting release of biochemical mediators. tPA: tissue plasminogen activator; NO:
nitric oxide; TFPI: tissue factor pathway inhibitor.
compression causing haemodynamic changes. Instead, In vitro studies of strain and shear and its clinical
relevance to IPCthe compressive forces of IPC also may have stimulated
the systemic fibrinolytic capacity or other biochemical
Plasminogen is plasma glycoprotein made primarilymechanisms of the circulation.
When IPC is applied to the lower extremity, the in the liver, which when activated by agents such as
tissue plaminogen activator (tPA), urokinase, strep-sudden compression causes a pulsatile flow to move
forward while resulting in entirely draining of blood tokinase, tears, colostrum, or semen, becomes plasmin
or fibrinolysin. It is known that plasminogen activatorat the compression site. The distention caused by the
rush of blood volume imposes a compressive strain inhibitor (PAI) can inhibit this plasminogen activity.
Plasminogens levels in plasma normally parallel fib-on the venous endothelial cells, while the increased
flow velocity imposes an increased shear stress on rinogen levels and are increased after trauma and
inflammation. tPA is produced by vascular endothelialthese same endothelial cells. This phenomenon also
translates to the arterial system when the sudden cells (especially from venous sources).33
The application of cyclic strain >7% on cultureddecrease in the venous pressure causes an increase in
the A–V pressure disparity leading to an increased bovine endothelial cells induced a significant increase
in immunoreactive tPA production. Moreover, im-arterial flow velocity. This effect increases shear stress
on arterial endothelial cells. The mechanical forces of munocytochemical detection of intracellular tPA and
mRNA expression of tPA significantly increased instrain and shear have been shown in animal and cell
culture models to cause physiological responses in endothelial cells subjected to more than 7% cyclic
strain.34,35 Cyclic strain also resulted in a 2.6-fold in-endothelial cells that may contribute to the anti-
thrombotic, pro-fibrinolytic, and vasodilatory effects crease in the activity of the 1.4-kb tPA promoter after
4 h.36 The frequency of the mechanical stretch in theseof IPC (Fig. 1).
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in vitro studies was set to approximate the heart rate in the six healthy individuals. Moreover, it was not
until the patients were stimulated by IPC that the(60 cycles/min), mimicking the strain caused by the
beating heart on arterial endothelial cells. The rel- patients’ fibrinolytic activity levels reached the levels
observed in normal individuals. These investigatorsevance of these in vitro studies to IPC physiology
remains speculative. Although IPC imposes strain on also found a significant increase in fibrinolytic activity
after 180 min of IPC exposure in normal subjects and inendothelial cells at a much lower frequency (1–2 cycles
per minute), one could speculate that it may produce the postthrombotic patients. The tPA activity increased
only in normal subjects, despite a decrease in tPAsimilar results. Nonetheless, these in vitro studies do
provide a foundation for designing a model which antigen, which occurred in both groups. Furthermore,
the study found decreases in PAI-1 antigen and in PAImore closely resembles the physiological environment
created by IPC. Further research is needed to test these activity levels in both groups after IPC exposure. The
investigators postulated that fibrinolytic activity wasspeculations.
When cultured endothelial cells are subjected to more critically related to the PAI-1 activity rather than
the total amount of tPA present in circulation (asarterial shear stresses of 15 and 25 dynes/cm2, the tPA
secretion rate was 2.1 and 3.0 times greater, re- measured by tPA-antigen). Hence, it was the balance
of PAI-1 activity, which was a function of total PAI-1spectively, than the basal tPA secretion rate.37 tPA
mRNA levels were also increased greater than 10-fold (PAI-1-antigen) and tPA-PAI-1 complexes in the cir-
culation, and total free tPA-antigen that determinedwhen compared to stationary controls.38 Although tPA
mRNA expression was decreased to 10% of stationary fibrinolytic capacity. IPC shifted this balance to favour
increased fibrinolysis45 (Fig. 2).control by low shear stress, tPA mRNA expression was
increased over 250% at high shear stress in vascular The effects of IPC on PAI-1 activity and total tPA in
the circulation have also been studied. After obtainingsmooth muscle cells.39 Increased shear stress on vas-
cular cells, though unproven, probably occurs when femoral venous catheter blood samples, it was found
that catheter placement caused elevation in PAI-1 andvenous and arterial blood flow in the lower extremities
increase secondary to IPC. tPA-PAI complex, giving clues to why the presence of
intravenous catheters are prothrombotic. However,Whether or not the increased release of tPA by
endothelial cells accounts for the therapeutic effects of IPC induced significant increases in fibrinogen de-
gradation products, and fibrin degradation products,IPC is still unclear. It has been postulated that fib-
rinolytic enhancement results in a decrease in the but decreased euglobulin lysis time. Furthermore, IPC
had no definitive effect on total tPA levels in theeuglobulin lysis time.40 Preoperative euglobulin lysis
time was found to be a good predictor of the de- circulation. It was proposed that perhaps the increased
tPA is complexed with PAI-1 leading to an increase invelopment of postoperative DVT. It was also noted
that there is a decline in fibrinolytic activity in the the level of tPA-PAI-1 complexes. The data also showed
a decrease in total PAI-1, suggesting that the decreaseimmediate postoperative period.41 IPC was found to
reduce or even eliminate this decline in fibrinolytic may be secondary to increase consumption of PAI-1
from increase tPA secretion by endothelial cells afteractivity.42,43 After IPC was applied to the upper ex-
tremities, a similar increase in fibrinolytic activity was IPC exposure.46
However, these findings did not go unchallenged.found, as suggested by a decreasing trend in
euglobulin clot lysis time.44 Many investigators have In a study of 21 healthy individuals, euglobulin lysis
time, tPA antigen, PAI-1 antigen, and PAI-1 activityproposed that the increase in fibrinolytic activity was
secondary to increase tPA release from endothelial measurements showed that IPC did not cause any
statistically significant changes in any of parameterscells.43
In an important study, Comerota and colleagues used to measure fibrinolysis. The authors noted that
circadian rhythm seemed to have more influence onproposed a mechanism by which IPC increased fib-
rinolytic activity.45 They studied six healthy volunteers fibrinolysis than IPC.47 This finding was confirmed by
another study of 10 healthy volunteers which foundand six post-thrombotic patients. After the subjects
were exposed to IPC, their blood was drawn from that although increases in venous flow velocity were
seen in the common femoral vein, no changes in tPAan anticubital venous catheter. Fibrinolytic activity
(euglobulin fraction, fibrin plate assay), tPA antigen or PAI-1 antigens were observed with IPC.48 In a recent
study of 48 patients undergoing abdominal surgicaland activity, plasminogen activator inhibitor-1 (PAI-
1) antigen and activity and other components were procedures, the effects of IPC, and heparin injections
on systemic fibrinolysis were compared. This was doneassayed. In the six post-thrombotic patients, the base-
line fibrinolytic activity was significantly less than that by measuring tPA and PAI-1 by amidolytic methods.
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Fig. 2. Possible mechanical effects of intermittent pneumatic compression on fibrinolysis. IPC: intermittent pneumatic compression; PAI:
plasminogen activator inhibitor; tPA: tissue plasminogen activator; uPA: urokinase plasminogen activator.
Fig. 3. Mechanical effects of intermittent pneumatic compression on the coagulation pathway. HMW: high molecular weight; TF: tissue
factor; F: factor; TFPI: tissue factor pathway inhibitor; IPC: intermittent pneumatic compression.
Although the study was able to show that post- resolve the issue of whether IPC affects systemic fib-
rinolysis.operative reduction in fibrinolytic activity did occur,
there were no appreciable changes in tPA activity or The importance of a tissue factor pathway inhibitor
as an important regulator of the initiating event inPAI-1 activity. The authors concluded that IPC had no
effect on the postoperative decrease in fibrinolytic blood coagulation in the extrinsic coagulation system
or the tissue factor pathway has also been recentlyactivity and that its therapeutic effect on DVT pro-
phylaxis was purely a result of altered haemodynamics appreciated.50 When factor VIIa (activated form of
factor VII) is complexed with tissue factor (TF), it willthat reduced lower extremity venous stasis.49 These
conflicting data suggest further study is needed to activate factor X and IX, ultimately leading to the
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Table 2. Mechanical effects of intermittent pneumatic compression.
Intermittent
Pneumatic
Compression
Blood Vessel
Stretch on EC’s20
Shear on EC’s
Nitric Oxide Synthesis62–66
Prostacyclin53, 57–60
Plasminogen Activator Inhibitor45, 46
Tissue Plasminogen Activator34–39
Venous Pressure23
AV Gradient24
Arterial Flow25, 26
Stasis21, 23
Interstitial Fluid Return To
Circulation29
Tissue Factor Pathway Inhibitor50–52
Other Unknown Mechanical/
Biochemical Effects.
?
Luminal Flow21,23
Contraction
Stretch (Strain)
Interstitial
Pressure
Muscle
Subcutaneous
Tissue
?
activation of prothrombin and subsequently thrombin, its impact on platelet aggregation. Prostacyclin, an
endothelial released autacoid, is the most potent endo-culminating in coagulation. Tissue factor pathway in-
hibitor directly inhibits factor Xa and the TF-factor genous inhibitor of platelet aggregation known. It
stimulates platelet disaggregation, and is a potentVIIa complex.50 Since heparin elevates tissue factor
pathway inhibitor, its anticoagulating effect may at inhibitor of smooth muscle cell contractions causing
vasodilatation. Prostacyclin elevates levels of adenylleast partly be the result of the physiological effect
of tissue factor pathway inhibitor on the extrinsic cyclase with an increase in cAMP, decreasing ionised
calcium and inhibiting aggregation.54,55 It also increasescoagulation system.51
Another antithrombotic mechanism of IPC has been red blood cell deformity, to facilitate blood flow in
vasculature with high resistance.33 Prostacyclin alsoproposed. In a study of six healthy individuals and
six patients with post-thrombotic venous disease, the has a pro-fibrinolytic effect as demonstrated by a study
which found increased levels of tPA activity withinvestigators found that after exposing the individuals
to IPC for 180 min there was a significant increase in shortened euglobulin clot lysis time in patients treated
with prostacyclin and iloprost (a stable analogue ofthe plasma tissue factor pathway inhibitor levels in
both groups. Moreover, there was also a significant prostacyclin) infusions.56
After exposing cultured endothelial cells to cyclicdecrease in the level of activated factor VII (VIIa) in
both groups and an inverse relationship between the strain of 24% at cycles of 10 s of elongation followed
by 10 s of relaxation, the prostacyclin synthetic capacitylevel of tissue pathway inhibitor and factor VIIa. It
has been postulated that the increase in tissue factor increased in a time-dependent manner.57 Prostacyclin
release was also enhanced in endothelial cells subjectedpathway inhibitor after IPC exposure was likely a
result of increased release of the inhibitor from within to elevated shear stress.58,59 When intact human um-
bilical vein conduits were subjected to 25 dyn/cm2,endothelial cells or from the cellular surface.52 This
form of issue factor pathway inhibitor is more effective there was upregulation of prostacyclin synthase after
6 h and an increased accumulation of alpha 6-ketoin anticoagulation than the truncated inhibitors bound
to lipoprotein in plasma.53 The increase in tissue factor prostaglandin, the stable metabolite of prostacyclin,
in the perfusion medium.60 These in vitro data arepathway inhibitor and the concomitant decrease in
factor VIIa levels are likely to be contributing factors supported by a clinical study. In a prospective study
of 26 patients undergoing surgery, there was an eleva-by which IPC prevents venous thrombosis52 (Fig. 3).
Another pathway by which IPC works may be in tion in the level of 6-Keto-prostaglandin-F1a in the
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femoral vein plasma when obtained from an extremity endothelial cells by IPC in vivo are unknown. The in
vitro studies do provide an attractive model to test theundergoing external IPC.61
Vasodilation is another possible mechanism by postulate that the mechanoreceptors in endothelial
cells, when activated, lead to a myriad of biochemicalwhich IPC improves perfusion in patients with arterial
occlusive disease. Endothelial cells produce an endo- processes consisting of enhanced fibrinolysis, platelet
disaggregation, and vasodilatation. Currently, an inthelium-derived relaxing factor identified as nitric
oxide. Like prostacyclin, nitric oxide is a potent in- vivo model that could accurately mimic the physio-
logical effects of IPC in humans is still lacking. Untilhibitor of smooth muscle cell contractions, which
causes vasodilation. Nitric oxide also inhibits platelet such a model is incorporated into new experimental
designs, definitive answers to the mechanistic actionsaggregation, stimulates disaggregation, inhibits plate-
let and monocyte adhesion to endothelial surfaces, of IPC cannot be fully addressed. Nonetheless, the
clinical studies do support the notion that IPC’s effectsand inhibits smooth muscle cell proliferation. Nitric
oxide is released following vascular injury by mech- are not purely mechanical and that the release of
biochemical mediators may play a role that is at leastanical or biochemical stimuli. Its production however,
is markedly diminished following reperfusion of as important. The reviewed studies provide strong
foundations on which further studies could be de-ischaemia.62
Studies have shown that when cultured endothelial signed to accurately predict the mechanical outcome
of IPC and its biochemical consequences.cells were exposed to shear mechanical stress (lamina
flow at 16 to 20 dynes per cm2), endothelial nitric oxide
synthase mRNA is up-regulated.63 Increased shear on
the superior mesenteric artery of rats also increased
nitric oxide synthesis.64,65 Moreover, when cultured References
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